ascenion
clear

 

Noteworthy

Owner by default

On 1 October 2009, the German Act on the Simplification and Modernisation of the Patent Law (Gesetz zur Vereinfachung und Modernisierung des Patentrechts) came into force. Most important to German public research organizations and universities is a modification to the Employees’ Invention Law (Arbeitnehmererfindungsgesetz). Under the previous law, the employer had to formally CLAIM an invention by written notice to the employee if he wanted to receive all the rights associated with the invention, e.g. for its commercial exploitation. If he failed to do so within four months from the receipt of an invention disclosure statement, the inventor remained the owner of his or her invention. According to the new law, the employer will automatically become the owner of an invention made by an employee if he does not formally RELEASE it within four months. However, what remains unchanged is that ownership comes with a duty for the employer: he has to file for patent protection, at least in Germany, and let the inventor participate in future returns from commercialization.  

Meet us at the forthcoming events:

Biotech-NetWorkshop, 24-26 February 2010, Schloss Ringberg (Tegernsee), Germany
www.ascenion.de

BioVaria, 20 April 2010, Munich, Germany
www.BioVaria.org

BIO International Convention, 3-6 May 2010, Chicago, USA
http://convention.bio.org

ASTP 10th anniversary, 27-28 May 2010, Paris, France
www.astp.net

News in Brief:


Helmholtz Zentrum München renews alliance with Ascenion
Ascenion and the Helmholtz Zentrum München have recently agreed to continue their long-term collaboration.more

 
HKI becomes member of the Life-Science Foundation
Following four years of collaboration with Ascenion, the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI) joined Ascenion’s parent holding, the Life-Science Foundation for the Promotion of Science and Research.more


DPZ extends license agreement for its antibody against prions
The DPZ anti-prion antibody has been licensed to the French Atomic Energy Commission (CEA, Commissariat à l'énergie atomique) for a further 10 years, to be used as part of an antibody cocktail that is exclusively sublicensed to Bio-Rad.more


NovaTec to commercialize new test for chikungunya fever
A team of researchers from the Bernhard Nocht Institute for Tropical Medicine (BNI), a member of the Leibniz Association, and the German Federal Armed Forces has developed a new ELISA for the diagnosis of chikungunya infections. more


Ascenion acquires shares in BITZ
Ascenion now holds equity in BITZ (Braunschweiger Informatik- und Technologie-Zentrum) gGmbH – a joint venture of the Technical University Braunschweig, the Helmholtz Centre for Infection Research (HZI) and the software and consulting company Lineas.
more


Ascenion team news
Marsha Schade joined the Munich team in September 2009 to support the Technology Transfer Competence Centre (KTT), the central service unit for technology transfer and communication within the Federal Program of Medical Genome Research.

Isabell Schwenkert joined the Hanover team in September 2009 as technology scout. Together with her colleague Ralf Cordes, she will work with scientists from the Hanover Medical School (MHH).more


Contact us:

Munich:
T +49 89 318814-0
info(at)ascenion.de

Berlin:
T +49 30 9406 230 -1/-4
berlin(at)ascenion.de

Braunschweig:
T +49 531 6181 2090
braunschweig(at)ascenion.de

Hamburg:
T +49 40 22611 278
hamburg(at)ascenion.de

Hanover:
T +49 511 5328 921
hanover(at)ascenion.de

Neuherberg:
T +49 89 3187 2850
neuherberg@ascenion.de

Ascenion GmbH, www.ascenion.de